Adalta Ltd. · ASX:1AD
Adalta — ISCT ANZ 2026 Regional Meeting
14 slides from Adalta's conference presentation, Jul 20, 2026
Slide 1: ISCT ANZ 2026 oral presentation and poster
ASX Announcement | 20 July 2026 AdAlta Limited (ASX:1AD) ISCT ANZ 2026 oral presentation and poster Recognition of AdAlta’s unique ‘East to West’ model for bringing groundbreaking cellular immunotherapies for cancer to patients worldwide Investment highlights • AdAlta’s abstract describing its ‘East
Slide 2: About EW-001 (formerly BZDS1901) and About AdAlta
About EW-001 (formerly BZDS1901) EW-001 is a novel, first in class, CAR-T cell therapy designed to treat mesothelioma (a rare but rapidly fatal cancer usually linked to asbestos exposure) and with possible application in more than ten other cancers. CAR-T cell therapies are living drugs manufactured
Slide 3: AD-214 and more information
AdAlta’s first in class fusion protein, AD-214, takes a whole new approach to fibrotic diseases of the lung and kidney, such as the degenerative and fatal Idiopathic Pulmonary Fibrosis. Following demonstration of efficacy in multiple animal models of disease and two successful Phase I clinical studi
Slide 4: East to West: Commercialising Asian cell therapy innovation for Western markets
For personal use only “East to West” Commercialising Asian cell therapy innovation for Western markets Tim Oldham, CEO & Managing Director, AdAlta Ltd Bo Zhang, Vice President, Shanghai Cell Therapy Group Co Ltd Bev Menner, CEO, Cell Therapies Pty Ltd Jason Foster, CEO and Executive Director, Oribio
Slide 5: AdAlta's unique East to West business model
ADALTA’S UNIQUE “EAST TO WEST” BUSINESS MODEL BRINGS “EASTERN” INNOVATION TO “WESTERN” PATIENTS A repeatable arbitrage between Asia's innovation surplus and the West's access deficit - proven by a first asset in the clinic For personal use only Differentiated Capital efficient De-risked Scalable • T
Slide 6: Solid cancer CAR-T is the next frontier
SOLID CANCER CAR-T IS THE NEXT FRONTIER T cell therapies are living drugs: a patient's own T cells, re-engineered to find and kill cancer - offering durable, potentially curative responses from a single treatment For personal use only CAR T-Cell therapy: turbo charges the immune system to see and ki
Slide 7: The opportunity: Eastern innovation surplus that can't reach Western patients
THE OPPORTUNITY: EASTERN INNOVATION SURPLUS THAT CAN'T REACH WESTERN PATIENTS China has a deep pool of clinical-stage cell therapies, but few have a credible, compliant path to access Western approval and reimbursement For personal use only The innovation surplus (“East”) The access deficit (barrier
Slide 8: The model: in-license cheaply, Westernise, exit, recycle
THE MODEL: IN-LICENSE CHEAPLY, WESTERNISE, EXIT, RECYCLE Unit economics For personal use only per asset In-license Add value Exit ~US$15m Recycle All-in investment per asset to exit (“East”) (“West”) (on-license) • Acquire highly • Phase 1 in Australia • License the de- • Retain regional rights 3-4
Slide 9: EW-001: a stand-out armoured MSLN CAR-T for solid cancers
EW-001: A STAND-OUT ARMOURED MSLN CAR-T FOR SOLID CANCERS MSLN-targeted, anti-PD1 nanobody-armoured autologous CAR-T. Developed as BZDS1901 by, and licensed from, Shanghai Cell Therapy Group (SHcell); exclusive rights outside greater China (7 patent families). • Mesothelin (MSLN) is highly expressed
Slide 10: Complete responses: the highest-value early signal in solid tumour CAR-T
COMPLETE RESPONSES: THE HIGHEST-VALUE EARLY SIGNAL IN SOLID TUMOUR CAR-T EW-001 (BZDS1901) has produced complete responses - complete tumour clearance - in advanced mesothelioma. This is rare, and it is what changes the conversation with patients, regulators and acquirers. For personal use only Meso
Slide 11: EW-001 CAR-T results to date point to a better outcome
EW-001 CAR-T RESULTS TO DATE POINT TO A BETTER OUTCOME EW-001 (BZDS1901)’s CR rate supports accelerated / conditional approval pathways and anchors value in comparable-deal range For personal use only Lesion 1 Target Patient #03 Not good 5cm tumours Best change in tumor size cleared for more than 2
Slide 12: Built ecosystem: AdAlta's cell therapy advantage
BUILT ECOSYSTEM: ADALTA’S CELL THERAPY ADVANTAGE AdAlta uses mature, FDA-recognised Australian clinical and manufacturing infrastructure that is materially cheaper than the US. • Globally recognised early stage research Australia’s national For personal use only • 55 institutions treating patients w
Slide 13: For more information please contact
For personal use only FOR MORE INFORMATION PLEASE CONTACT: TIM OLDHAM CEO & MANAGING DIRECTOR +61 403 446 665 T.OLDHAM@ADALTA.COM.AU WWW.ADALTA.COM.AU AdAlta Ltd | ISCTANZ2026 Presentation | July 2026 | 10
Slide 14: An East-to-West business model for commercialising solid tumour CAR-T therapies (poster)
Abstract #: 138 AN EAST-TO-WEST BUSINESS MODEL FOR COMMERCIALISING SOLID TUMOUR CAR-T THERAPIES: LEVERAGING CROSS-BORDER PARTNERSHIPS, ADVANCED MANUFACTUIRNG AND CAPITAL EFFICIENT DEVELOPMENT Tim Oldham, Bo Zhang, Bev Menner, Jason Foster, Angus Tester a b c d a a. AdAlta Ltd, Melbourne, Australia,